Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Carleton University

$20,000.00

New Treatments for Chronic Pain Through Molecular Simulations of Ion Channel Blockades

FY 2024-25

Summary
Chronic pain is a persistent and debilitating condition affecting many individuals. Traditional pain medications can have side effects and limitations. WEX Pharmaceuticals has led the development of a radically-different approach for treating chronic pain using a natural substance called tetrodotoxin. At high doses, this compound is toxic, but clinical trials conducted by WEX have shown that it can have a strong and durable effect in reducing chronic pain. This research project will use computer simulations to develop a more complete understanding of how tetrodotoxin interacts with nerve cells in the body. Tetrodotoxin is understood to interact with protein channels in the membrane of nerve cells that control the passage of sodium ions, although some of the variants of these channels are resistant to these effects. Our simulations will model how tetrodotoxin interacts with these channels to determine how they are exerting their modulating effect and why this effect is different for different channels. These simulations will support the development of new tetrodotoxin-based therapies and the development of new therapeutic agents that act through similar mechanisms.
Program
Alliance Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
590253-2023
Name nom
Rowley, Christopher CNM
Department département
Chemistry
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
20000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3155
Research subject group en
Theoretical physics and chemistry
Research subject group fr
Physique et chimie théoriques
Research subject en
Statistical mechanics and thermodynamics
Research subject fr
Mécanique statistique et thermodynamique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
New Treatments for Chronic Pain Through Molecular Simulations of Ion Channel Blockades
Keywords
ion channel blockades; ion channels; molecular dynamics; molecular simulation; sodium channels; tetrodotoxin
Application summary
Chronic pain is a persistent and debilitating condition affecting many individuals. Traditional pain medications can have side effects and limitations. WEX Pharmaceuticals has led the development of a radically-different approach for treating chronic pain using a natural substance called tetrodotoxin. At high doses, this compound is toxic, but clinical trials conducted by WEX have shown that it can have a strong and durable effect in reducing chronic pain. This research project will use computer simulations to develop a more complete understanding of how tetrodotoxin interacts with nerve cells in the body. Tetrodotoxin is understood to interact with protein channels in the membrane of nerve cells that control the passage of sodium ions, although some of the variants of these channels are resistant to these effects. Our simulations will model how tetrodotoxin interacts with these channels to determine how they are exerting their modulating effect and why this effect is different for different channels. These simulations will support the development of new tetrodotoxin-based therapies and the development of new therapeutic agents that act through similar mechanisms.